Details
Stereochemistry | ACHIRAL |
Molecular Formula | C20H29N5O6.ClH.H2O |
Molecular Weight | 489.95 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
O.Cl.COC1=CC2=C(N=C(N=C2N)N3CCN(CC3)C(=O)OCC(C)(C)O)C(OC)=C1OC
InChI
InChIKey=WXMXALSEIGHTOR-UHFFFAOYSA-N
InChI=1S/C20H29N5O6.ClH.H2O/c1-20(2,27)11-31-19(26)25-8-6-24(7-9-25)18-22-14-12(17(21)23-18)10-13(28-3)15(29-4)16(14)30-5;;/h10,27H,6-9,11H2,1-5H3,(H2,21,22,23);1H;1H2
Molecular Formula | C20H29N5O6 |
Molecular Weight | 435.4742 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Molecular Formula | H2O |
Molecular Weight | 18.0153 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Molecular Formula | ClH |
Molecular Weight | 36.461 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Trimazosin was originated by Pfizer and was licensed to Bristol-Myers Squibb worldwide except for Canada, Mexico and the USA. Trimazosin is a quinazoline antihypertensive agent structurally related to the selective alpha 1-adrenoceptor blocker prazosin. Trimazosin is an alpha adrenergic receptor antagonist. Compared with prazosin, trimazosin was a less potent but more efficacious hypotensive agent. At doses which caused equal or even greater hypotensive effects than those caused by prazosin, trimazosin caused less inhibition of pressor responses to phenylephrine. When administered during a maximum hypotensive response to prazosin, trimazosin caused an additional fall in pressure. Trimazosin is an effective antihypertensive when given by itself or in combination with a diuretic. Its ability to induce vasodilation without concomitant sodium retention or stimulation of the renin axis may be an important factor in its effectiveness. Trimazosin has the potential to cause sustained improvement in left ventricular function, both at rest and during exercise, in patients with chronic congestive heart failure (CHF).
Originator
Approval Year
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/7042174
Trimazosin was given for periods of at least 6 mo to 25 patients with mild to moderate essential hypertension. In doses of 300 to 900 mg dialy trimazosin alone led to blood pressure control (supine diastolic blood pressure less than 90 mm Hg with a fall of at least 10 mm Hg) in 16 patients (64%).
Route of Administration:
Oral
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 15:14:14 GMT 2023
by
admin
on
Fri Dec 15 15:14:14 GMT 2023
|
Record UNII |
827T79ILE7
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C29713
Created by
admin on Fri Dec 15 15:14:14 GMT 2023 , Edited by admin on Fri Dec 15 15:14:14 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
DTXSID40202021
Created by
admin on Fri Dec 15 15:14:14 GMT 2023 , Edited by admin on Fri Dec 15 15:14:14 GMT 2023
|
PRIMARY | |||
|
64749
Created by
admin on Fri Dec 15 15:14:14 GMT 2023 , Edited by admin on Fri Dec 15 15:14:14 GMT 2023
|
PRIMARY | |||
|
DBSALT001792
Created by
admin on Fri Dec 15 15:14:14 GMT 2023 , Edited by admin on Fri Dec 15 15:14:14 GMT 2023
|
PRIMARY | |||
|
CHEMBL513301
Created by
admin on Fri Dec 15 15:14:14 GMT 2023 , Edited by admin on Fri Dec 15 15:14:14 GMT 2023
|
PRIMARY | |||
|
m978
Created by
admin on Fri Dec 15 15:14:14 GMT 2023 , Edited by admin on Fri Dec 15 15:14:14 GMT 2023
|
PRIMARY | Merck Index | ||
|
C75060
Created by
admin on Fri Dec 15 15:14:14 GMT 2023 , Edited by admin on Fri Dec 15 15:14:14 GMT 2023
|
PRIMARY | |||
|
C005185
Created by
admin on Fri Dec 15 15:14:14 GMT 2023 , Edited by admin on Fri Dec 15 15:14:14 GMT 2023
|
PRIMARY | |||
|
827T79ILE7
Created by
admin on Fri Dec 15 15:14:14 GMT 2023 , Edited by admin on Fri Dec 15 15:14:14 GMT 2023
|
PRIMARY | |||
|
53746-46-6
Created by
admin on Fri Dec 15 15:14:14 GMT 2023 , Edited by admin on Fri Dec 15 15:14:14 GMT 2023
|
PRIMARY | |||
|
SUB04965MIG
Created by
admin on Fri Dec 15 15:14:14 GMT 2023 , Edited by admin on Fri Dec 15 15:14:14 GMT 2023
|
PRIMARY | |||
|
100000084664
Created by
admin on Fri Dec 15 15:14:14 GMT 2023 , Edited by admin on Fri Dec 15 15:14:14 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
PARENT -> SALT/SOLVATE | |||
|
ANHYDROUS->SOLVATE |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |